Clinical Trials Browser

Phase 2 × Completed × Virus Diseases × Clear all

DNA Virus Infections, Skin Diseases, Skin Diseases, Infectious, Tumor Virus Infections, Virus Diseases, Warts, Skin Diseases, Viral, Papillomavirus Infections

NCT03981822 2024-11-27

CARE-1

Phase 2 Completed

105 enrolled 24 charts

Condylomata Acuminata, Sexually Transmitted Diseases, Skin Diseases, Skin Diseases, Infectious, Virus Diseases, Warts, Sexually Transmitted Diseases, Viral, Skin Diseases, Viral, Papillomavirus Infections

NCT02482428 2021-01-05

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

Phase 2 Completed

88 enrolled 10 charts

Condylomata Acuminata, Sexually Transmitted Diseases, Virus Diseases, Papillomavirus Infections

NCT02868242 2020-03-02

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy

Phase 2 Completed

19 enrolled 14 charts

Hepatitis C, Liver Diseases, Virus Diseases, Hepatitis C, Chronic

NCT01136395 2019-10-08

Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation

Phase 2 Completed

85 enrolled

Virus Diseases, Epstein-Barr Virus Infections

NCT02724254 2018-07-20

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

Phase 2 Completed

218 enrolled

Condylomata Acuminata, Sexually Transmitted Diseases, Virus Diseases, Papillomavirus Infections

Clinical Trials

COVE-1

CARE-1

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy

Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients